tbuckley/cabot-search huggingface dataset:
51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
Authors: Ferda Cevikbas, Thomas Rouillé, Silvia Barbosa, Ana Steinhoff, Ilaria Piccini, Janin Edelkamp, Alexandre Kaoukhov, Carl Firth, Ferda Cevikbas, Marta Bertolini
Journal: Journal of the American Academy of Dermatology (2024)
54010 DISCRN: (D)ifferentiating (I)mmune (S)ignatures in (C)utaneous T-Cell Lymphoma and Atopic D(e)rmatitis Through Integrative Single-Cell (RN)A Sequencing Analysis
Authors: Oluwaseyi Adeuyan, Emily R. Gordon, Brigit A. Lapolla, Celine M. Schreidah, Lauren M. Fahmy, Caroline Chen, Larisa J. Geskin
Journal: Journal of the American Academy of Dermatology (2024)
52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial
Authors: Shoba Ravichandran, Andrzej Kaszuba, Dorota Krasowska, Nina Magnolo, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Philemon Papanastasiou, Kulli Kingo
Journal: Journal of the American Academy of Dermatology (2024)
51075 HADS anxiety and depression scores improved in Japanese patients with moderate-to-severe atopic dermatitis following lebrikizumab treatment: 16-week results from a randomized, double-blind, placebo-controlled phase 3 trial (ADhere-J)
Authors: Takeshi Nakahara, Yuichiro Tsunemi, Hitoe Torisu-Itakura, Yoji Morisaki, Evangeline Pierce, Martin Dossenbach, Hidehisa Saeki
Journal: Journal of the American Academy of Dermatology (2024)
52741 Efficacy of Abrocitinib Versus Dupilumab on Dermatitis in the Head-and-Neck Region of Patients With Moderate-To-Severe Atopic Dermatitis: A Post Hoc Analysis of the Phase 3 JADE DARE Study
Authors: April W. Armstrong, Melinda J. Gooderham, Kilian Eyerich, Kristian Reich, Andrew Blauvelt, H. Chih-ho Hong, Roger A. Edwards, Gianluca Bonfanti, Gary Chan, Erman Güler, Claire Feeney
Journal: Journal of the American Academy of Dermatology (2024)
50629 Impact of Achieving F-VASI 75 or T-VASI 50 on Patient- and Physician-Reported Outcomes in Patients With Non-Segmental Vitiligo (NSV) Receiving Upadacitinib During a Phase 2 Study
Authors: David Rosmarin, Ahmed M. Soliman, Yazan K. Barqawi, Chao Li, Bethanee J. Schlosser, Khaled Ezzedine
Journal: Journal of the American Academy of Dermatology (2024)
52204 INAUGURAL REPORT OF RECESSIVE KRT1 WITH A NOVEL MUTATION IN SUPERFICIAL EPIDERMOLYTIC ICHTHYOSIS COMBINED WITH HYPERTRICHOSIS
Authors: Minh Van Hoang, Bao Chi Bui, Anh Quynh Ngoc Phan, Vien The Tran, Tri Cao Le, Vy Truc Hoang Nguyen, Nguyen Phan Nguyen, Giang Huong Tran, Phung Kim Thi Ngo
Journal: Journal of the American Academy of Dermatology (2024)
51454 Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial
Authors: Loretta Fiorillo, Emily Becker, Susana Armesto, Amy S. Paller, Apostolos Kontzias, Rajneet K. Oberoi, Yuri Klyachkin, Hamid Amouzadeh, Zuoshun Zhang, Lisa Arkin
Journal: Journal of the American Academy of Dermatology (2024)
Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year Olds to Detect Atrial Fibrillation -STROKESTOP II
Authors: Katrin Kemp Gudmundsdottir, Emma Svennberg, Leif Friberg, Tove Hygrell, Viveka Frykman, Faris Al-Khalili, Ziad Hijazi, Marten Rosenqvist, Johan Engdahl
Journal: Circulation (2024)

Background: Guidelines have suggested screening for atrial fibrillation to enable early treatment and avoid downstream negative clinical events. We aimed to determine if atrial fibrillation screening potentially enhanced by NT-proBNP would reduce stroke or systemic embolism incidence as compared to in a control group and to determine if it was safe for those with low NT-proBNP concentrations to forfeit prolonged screening. Methods: In this randomized controlled trial all 75/76-year-old individuals in Stockholm Region, Sweden were randomized 1:1 to be invited to screening or serve as a control group. NT-proBNP concentration were measured and a single-lead-ECG registered only once if NT-proBNP&lt;125ng/L, whereas if NT-proBNP≥125 ng/L participants underwent prolonged screening, recording single-lead ECGs four times daily for two weeks. If atrial fibrillation was detected, treatment was initiated. Baseline and outcome data were collected from Swedish National Registries. Results: In total 28,712 individuals were randomized, after exclusion of death and emigration 13,905 remained in the intervention group, 13,884 in the control group. Participation rate in the intervention group was 49.2% (6,843/13,905). Participants in the high NT-proBNP group (NT-proBNP≥125 ng/L) without prior atrial fibrillation constituted 60% of the total and underwent prolonged screening. New AF was detected in 2.4% (165/6,843) in the intervention group. There was no difference in AF prevalence or oral anticoagulant treatment between the intervention and the control group after five years follow-up. After a median of 5.1 years (IQR 5.0-5.8) there was no difference in the primary outcome of stroke or systemic embolism between the intervention group and the control group, HR: 0.96 (95% CI 0.86-1.06). The low NT-proBNP-group had significantly fewer strokes or systemic emboli than the control group, HR: 0.59 (95% CI 0.46-0.74), p&lt;0.001. In the high NT-proBNP group the risk of stroke or systemic embolism was higher compared to the low NT-proBNP group, HR: 1.57 (95% CI 1.22-2.02), p=0.001. Conclusions: In this population-based screening trial for atrial fibrillation using NT-proBNP for screening enhancement, there was no difference in risk of stroke or systemic embolism for the intervention group compared to controls. Participation was moderate. The use of NT-proBNP for screening enhancement was safe in identifying low-risk participants. Clinical Trial Registration: www.clinicaltrials.gov; NCT02743416
50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study
Authors: Linda Stein Gold, Stephen Keith Tyring, H. Chih-ho Hong, Lev Pavlovsky, Andreas Pinter, Adam Reich, Tianshuang Wu, Vassilis Stakias, Sven Richter, Kim A. Papp
Journal: Journal of the American Academy of Dermatology (2024)
50699 Pembrolizumab-Induced Lichenoid Drug Eruption Successfully Treated with Dupilumab – A Case Report
Authors: Jason Eakes, Leigh Hatch, Kerry Hennessy, Sairekha Ravichandran, Noura Ayoubi, Kayla Fourzali, Julie Yi, Amanda Krenitsky, Alison Kucharik, Lilia Correa
Journal: Journal of the American Academy of Dermatology (2024)
50969 Associations and Comorbidities between Psoriasis and Allergic Rhinitis and Asthma: A Retrospective Cross-Sectional Analysis
Authors: Brandon Ansbro, Amy Paller
Journal: Journal of the American Academy of Dermatology (2024)

Introduction: Psoriasis is an autoimmune disorder characterized by Th1, Th17, and Th22 chronic inflammation. The relationship between psoriasis and Th2-mediated atopic disorders is not understood.
53907 Amlitelimab improves extent and severity of disease in adults with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)
Authors: Stephen Weidinger, Ken Igawa, Efstathios Zikos, Christine Weber, Wanling Wong, Cori Gray, Andrew Blauvelt
Journal: Journal of the American Academy of Dermatology (2024)
54139 Relative utilization of Mohs micrographic surgery or wide local excision for melanomas of the head &amp; neck melanomas versus trunk and extremities: A multisite analysis from 2007-2022
Authors: Mara Trifoi, Daniela Frankel, Karla Morales-Valdes, Marissa Lubeck, Jeremy R. Etzkorn, Christopher J. Miller
Journal: Journal of the American Academy of Dermatology (2024)
53081 Dupilumab Treatment Provides Sustained Improvement in Skin Barrier Function, Clinical Outcomes, and Patient-Reported Outcomes in Patients Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis
Authors: Michael J. Cork, Peck Ong, Simon G. Danby, Marco Ramirez-Gama, Shannon Garcia, Patricia Taylor, Joseph Zahn, Gabriel Bologna, Annie Zhang, Donald Y.M. Leung
Journal: Journal of the American Academy of Dermatology (2024)
52968 Association of Time to Definitive Surgery with Outcomes in Mohs Micrographic Surgery for Non-Melanoma Skin Cancers: A Retrospective Cohort Study
Authors: Davies Gage, Katherine G. Thompson, Raghav Tripathi, Christian Hopkins, Emanuelle Rizk, Yu Jui Kung, Karen Tai, Kristin P. Bibee, Jeffrey F. Scott
Journal: Journal of the American Academy of Dermatology (2024)
51887 Lebrikizumab Demonstrates Sustained Efficacy in Adolescent Patients Through 2 Years of Continuous Treatment: Results From ADjoin Long-Term Extension
Authors: Amy Paller, Antonio Torrelo, Chin-Yi Yang, Candrice Heath, Carsten Flohr, Stephan Weidinger, Hany Elmaraghy, Louise DeLuca-Carter, Fan Emily Yang, Clara Armengol, Lawrence Eichenfield
Journal: Journal of the American Academy of Dermatology (2024)
51783 A novel biomarker of type VII collagen degradation is increased in patients with atopic dermatitis and lowered when receiving immunosuppressant treatment.
Authors: Matej Andelic, Jesper Grønlund Holm, Alexander Egeberg, Jacob P. Thyssen, Valdemar W. Nielsen, Morten Karsdal, Anne-Christine Bay-Jensen, Signe Holm Nielsen, Simon Francis Thomsen
Journal: Journal of the American Academy of Dermatology (2024)
54269 Patchy hair loss, hyperpigmented plaques, and hyperkeratotic papules in a middle aged woman
Authors: Mariela Irabien Zuñiga, Patrizia Elva Aguilar Calderón, Debanhi Kassandra Luna Garza, Alejandra Brown Herrera, Jorge Ocampo Candiani, Sonia Sofia Ocampo Garza
Journal: Journal of the American Academy of Dermatology (2024)
53763 Dupilumab Improves Activity and Work Productivity Among Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1 Antihistamines
Authors: Gil Yosipovitch, Marcus Maurer, Ana M. Giménez-Arnau, Heike Rockmann-Helmbach, Naoko Inomata, Luis Felipe Ensina, Philip Sugerman, Jerome Msihid, Sonya Cyr, Ryan B. Thomas, Chien-Chia Chuang
Journal: Journal of the American Academy of Dermatology (2024)
51363 Growth Analysis in Children Aged Less Than 12 Years with Moderate-to-Severe Atopic Dermatitis
Authors: Amy Paller, Bob Geng, Alan Irvine, Elaine Siegfried, Michael Cork, Michele Ramien, Lawrence Eichenfield, Rajan Gupta, Bryan Adams, Marius Ardeleanu, Annie Zhang
Journal: Journal of the American Academy of Dermatology (2024)
50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis
Authors: Linda Stein Gold, Marie Louise Schuttelaar, Vimal H. Prajapati, Bernhard Homey, Lindsay Strowd, Martin Dossenbach, Chunyuan Liu, Jinglin Zhong, Evangeline Pierce, Helena Agell, Juan Francisco Silvestre
Journal: Journal of the American Academy of Dermatology (2024)
52132 Real-world experience of switching atopic dermatitis treatment to upadacitinib after primary or secondary dupilumab failure
Authors: Belen de Nicolas-Ruanes, Emilio Berna-Rico, Emilio Garcia-Mouronte, Carlos Azcarraga-Llobet, Asuncion Ballester-Martinez, Daniel Ortega-Quijano, Gonzalo Segurado-Miravalles, Diego Fernandez-Nieto, Bibiana Perez-Garcia
Journal: Journal of the American Academy of Dermatology (2024)
48964 Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-Severe Atopic Dermatitis
Authors: Akio Tanaka, Ken Igawa, Hidestoshi Takahashi, Ryoshuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Sonia Montmayeur, Norito Katoh
Journal: Journal of the American Academy of Dermatology (2024)
52765 Lack of correlation between number of baseline actinic keratoses (AKs) and local tolerability signs (LTS) severity in patients treated with tirbanibulin over a 100 cm2 area: results from a Phase 3 study
Authors: Neal Bhatia, Edward Lain, Abel Jarell, Marie Pierre Malice, Laura Padullés, Raquel Otero, Andrew Blauvelt
Journal: Journal of the American Academy of Dermatology (2024)
53782 Dupilumab Improves Sleep Quality in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1 Antihistamines
Authors: Gil Yosipovitch, Marcus Maurer, Ana M. Giménez-Arnau, Heike Rockmann-Helmbach, Naoko Inomata, Luis Felipe Ensina, Philip Sugerman, Jerome Msihid, Sonya Cyr, Ryan B. Thomas, Chien-Chia Chuang
Journal: Journal of the American Academy of Dermatology (2024)
50997 A phase II trial of human bone marrow-derived clonal mesenchymal stem cells for treatment of adults with moderate-to-severe atopic dermatitis
Authors: Hyun-Min Seo, Bark-Lynn Lew, Sang Wook Son, Chang Ook Park, Jin-Ok Baek, Min Kyung Shin, Dong Hyun Kim, Hyun-Chang Ko, Dong-Sik Ham, Dong-Jun Kim, Gwang Seong Choi
Journal: Journal of the American Academy of Dermatology (2024)
49702 A longitudinal cohort study of squalene epoxidase gene mutations in U.S. onychomycosis patients from 2022 to 2023 – Implications for terbinafine resistance
Authors: Aditya Gupta, Tong Wang, Shruthi Polla Ravi, Elizabeth Cooper, Mary Bamimore, Sara Lincoln, Hui-Chen Foreman, Vincent Piguet, Wayne Bakotic
Journal: Journal of the American Academy of Dermatology (2024)
51536 Erosive Pustular Dermatosis-like Eruption of the Scalp Secondary to Amivantamab
Authors: Mariya George, Riyad Seervai, Susan Chon
Journal: Journal of the American Academy of Dermatology (2024)

Amivantamab is a bispecific monoclonal antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition proto-oncogene.1 Early studies report acneiform rash and paronychia as the most common cutaneous adverse events.1-2 Here, we present the first three reported cases of patients who developed painful, crusted erosions, superficial ulcerations on the scalp, and alopecia with onset ranging from weeks to months on amivantamab, consistent with an erosive pustular dermatosis (EPD)-like eruption. None of the patients had a history of radiation, trauma, or actinic damage to the scalp, or other risk factors associated with EPD.3 All patients had a preceding prodromal acneiform eruption and paronychia, followed by a disordered hypergranulation or ulcerations at additional sites. They all required interruption of their anticancer therapy and were treated with multiple rounds of oral antibiotics, steroids, and retinoids with poor response. Two patients required permanent discontinuation of amivantamab due to severe skin toxicity and progression of disease, with eventual resolution of their symptoms. Interestingly, one patient was able to continue amivantamab therapy with the initiation of low-dose dapsone, which has been shown to be effective in the management of other refractory or severe EGFR inhibitor-associated toxicities.4-6 Delay in diagnosis of EPD-like eruption due to its resemblance to other dermatological disorders can lead to increased morbidity and significant psychosocial implications. Given the severity and abrupt nature of the eruption, it is important for dermatologists to have a high clinical suspicion of EPD-like eruptions with amivantamab use to facilitate prompt treatment.
52104 Exploring the role of IL-36α, IL-36β, and IL-36γ in pyoderma gangrenosum: serum level evaluation and clinical correlations.
Authors: Magdalena Łyko, Anna Ryguła, Klaudia Rubas, Danuta Nowicka-Suszko, Joanna Maj, Alina Jankowska-Konsur
Journal: Journal of the American Academy of Dermatology (2024)
53833 Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial For up to 6 Years of Follow-up
Authors: Kim A. Papp, Mark G. Lebwohl, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Sven Richter, Tianshuang Wu, Ranjeeta Sinvhal, Simone Rubant, Michael M. Chen, Andrew Blauvelt
Journal: Journal of the American Academy of Dermatology (2024)
53197 Predictive biomarkers for response to omalizumab in patients with chronic spontaneous urticaria
Authors: Cristina Romera de Blas, María Cotarelo Hernández, Laura Sánchez Muñoz, Natalia Aranda Sánchez, M. Victoria Signes-Costa Smith, María José Carrera Hernández, Juan José Amorós Oliva, María Antonia Pastor Nieto, Isabel Sánchez Matas, Cristina Pérez Hortet, María Elena Gatica Ortega
Journal: Journal of the American Academy of Dermatology (2024)
50559 Concurrent exposure to multiple environmental aggressors amplifies damage in an ex-vivo human skin model; and the topical application of antioxidant-enriched sunscreens protects from multi-aggressor insults
Authors: Guangru Mao, John Ivarrson, Alessandra Pecorelli, Alexandra D’Arcangelis, Jin Namkoong, Joanna Wu
Journal: Journal of the American Academy of Dermatology (2024)
53117 Lower Total IgE After Dupilumab Treatment is Associated With a Reduction in Flares in Patients With Moderate-to-Severe Atopic Dermatitis
Authors: Brian Kim, Lisa A. Beck, Eric L. Simpson, Lawrence F. Eichenfield, Jonathan I. Silverberg, Kilian Eyerich, Shinichi Imafuku, Zhen Chen, Ana B. Rossi, Sonya L. Cyr
Journal: Journal of the American Academy of Dermatology (2024)

Background: Previous reports show that dupilumab treatment reduces IgE levels in patients with moderate-to-severe atopic dermatitis (AD). This analysis reports the impact of dupilumab-induced reduction in total IgE levels on flare probability in patients with moderate-to-severe AD.
52314 Isotretinoin for Management of Acne in Transgender Persons Receiving Masculinizing Hormone Therapy: A Multicenter Case Series
Authors: James Choe, Kanika Kamal, Sarah Gold, Austin Rios, Robin Wang, Jeromy Gotschall, Alana Ferreira, Emily Baumrin, Erica Dommasch, Jules Lipoff, Howa Yeung
Journal: Journal of the American Academy of Dermatology (2024)
53535 Integrative Analysis of Intermediate-to-High Risk Cutaneous Squamous Cell Carcinoma (cSCC)
Authors: Jacob Kechter, Angelina Hwang, Blake Boudreaux, Kevin Severson, Alysia Hughes, Tao Ma, Xing Li, David DiCaudo, Steven Nelson, Mark Pittelkow, Aaron Mangold
Journal: Journal of the American Academy of Dermatology (2024)
54224 Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies
Authors: Ryan Storgard, Rachel Reingold, Rose Parisi, Stephen Dusza, Sarah Noor, Jae Park, Craig Sauter, Kevin Curran, Miguel Perales, Michael Scordo, Alina Markova
Journal: Journal of the American Academy of Dermatology (2024)
48782 Hidradenitis Suppurativa-Associated Cutaneous Squamous Cell Carcinoma: A Cross-Sectional Analysis of the National Inpatient Sample.
Authors: Sach Thakker, Archana Samynathan, Pegah Bakhshi, Edward Hochman, Colin Wikholm, Helena Pasieka
Journal: Journal of the American Academy of Dermatology (2024)
51755 Factors associated with prolonged first stage tumor processing time in the Mohs laboratory
Authors: Stephanie K. Lin, Annika M. Deitermann, Marissa Lubeck, Christopher J. Miller, Jeremy R. Etzkorn, Harrison P. Nguyen, Umayr Shaikh, Dylan Haynes, Karla Valdes-Morales, Daniela Frankel, Joseph F. Sobanko
Journal: Journal of the American Academy of Dermatology (2024)
51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry
Authors: April W. Armstrong, Laura K. Ferris, Kristina Callis-Duffin, Adam P. Sima, Thomas Eckmann, Alicia Beeghly, Huzefa Photowala, Manish Patel, Vishvas Garg, Bruce E. Strober
Journal: Journal of the American Academy of Dermatology (2024)
52676 Safety and efficacy over one year of spesolimab treatment in patients with hidradenitis suppurativa (HS): Interim analysis of an open-label extension (OLE) study
Authors: Alexa B. Kimball, Asfaneh Alavi, Errol Prens, James G. Krueger, John W. Frew, Amit Garg, Sutirtha Mukhopadhyay, Hui Wang, Natalie B. Ivanoff, Ana Cristina Hernandez Daly, Christos C. Zouboulis
Journal: Journal of the American Academy of Dermatology (2024)
51361 Evaluation of the Performance of Two Broad-Spectrum Sunscreens Efficacy Using Reconstructed Human Skin Model
Authors: Hawasatu Dumbuya, Florence Canivet, Steven Durand, Damien Lelievre, Fabienne Thillou, Katharine Podimatis, Caroline Le Floc’h
Journal: Journal of the American Academy of Dermatology (2024)
51436 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 2.3 years and up to 4 Years of Exposure
Authors: Brett King, Arash Mostaghimi, Yutaka Shimomura, Bianca Maria Piraccini, Ulrike Blume-Peytavi, Angelina Sontag, Yves Dutronc, Katrin Holzwarth, Jill Kolodsick, Xiaoyu Lu, Rodney Sinclair
Journal: Journal of the American Academy of Dermatology (2024)
51977 Classification and Grading of Dermatologic Adverse Events from Anti-Cancer Therapies: A Multi-Center Study of Dermatology and Medical Oncology Physicians
Authors: Christopher Fay, Daniel Kim, Sean Singer, Ai-Tram Bui, Jolanta Pach, Christopher Iriarte, Rachel Reardon, Erica Huang, Nicole LeBoeuf
Journal: Journal of the American Academy of Dermatology (2024)
51609 Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
Authors: Alice B. Gottlieb, Joseph F. Merola, Barbara Ink, Rajan Bajracharya, Jérémy Lambert, Jason Coarse, Richard B. Warren
Journal: Journal of the American Academy of Dermatology (2024)
53743 Real-world Dupilumab Continuation in US Adults with Atopic Dermatitis Over a 24-month Period
Authors: J. Morel Symons, Janis Breeze, Stevan G. Severtson, Stefan Weiss, Urvee Karsanji, Sarah Nickolls, Dharm Patel
Journal: Journal of the American Academy of Dermatology (2024)
52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA
Authors: Kristen Lo Sicco, Jennifer Soung, Bruce Strober, Alan D. Irvine, Dalia Wajsbrot, Kimberly Gromek, Robert Wolk, David Barnes, Liza Takiya
Journal: Journal of the American Academy of Dermatology (2024)
54191 Nail Unit Atypical Intraepidermal Melanocytic Proliferation: Diagnostic Change to Melanoma and Local Recurrence Rate After Mohs Micrographic Surgery
Authors: Karla Valdes-Morales, Daniela Frankel, Mara Trifoi, Stephanie K. Lin, Annika M. Deitermann, Marissa M. Lubeck, Arturo J. Rios-Diaz, Jeremy R. Etzkorn, Daniel J. Lewis, Junqian Zhang, Christopher J. Miller
Journal: Journal of the American Academy of Dermatology (2024)
50585 ANB032, a B and T Cell Lymphocyte Attenuator (BTLA) Checkpoint Receptor Agonist, Modulates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Authors: German Muench, Eric Hare, Pejman Soroosh, Stephen Parmley, Paul Lizzul, Martin Dahl
Journal: Journal of the American Academy of Dermatology (2024)
51916 Associations between Obesity, Disease Severity, Comorbidities, and Medications in Pediatric and Adolescent Hidradenitis Suppurativa Patients: A Cohort and Cross-Sectional Analysis
Authors: Asfia Numani, Rachel Ziebart, Nessa Aghazadeh Mohandesi, Austin Todd, Afsaneh Alavi, Dawn Davis
Journal: Journal of the American Academy of Dermatology (2024)
54040 Efficacy of tirbanibulin for the treatment of actinic keratoses (AK): Comparison of results from randomized controlled trials (RCTs) and those from the real-world (RW) PROAK study
Authors: Todd Schlesinger, Ismail Kasujee, Raidah Salem, Paul Tomondy, Neal Bhatia
Journal: Journal of the American Academy of Dermatology (2024)
52680 Long-Term Safety Data for Dupilumab in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis
Authors: Robert Bissonnette, Lisa A. Beck, Mette Deleuran, Takeshi Nakahara, Ryszard Galus, Anna Coleman, Guy Gherardi, Jing Xiao, Elena Avetisova, Ariane Dubost-Brama, Arsalan Shabbir
Journal: Journal of the American Academy of Dermatology (2024)
52105 FAK Signaling and its Role in the Development of Brain Metastasis in Melanoma
Authors: Adriene Pavek, MiKaela Field, Jared Almazan, Tursun Turapov, Paulina Medellin-Alvarez, Mercedes Randhahn, Karly Stanley, Gennie Parkmann, Sheri Holmen
Journal: Journal of the American Academy of Dermatology (2024)